Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Dexcom. The associated price target remains the same with $100.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors including Dexcom’s proactive management of the G7 reliability concerns and the company’s confidence in achieving its 2025 targets. Despite a recent short report highlighting issues with the G7 sensor, Jennings believes these concerns are already reflected in the stock’s valuation.
Dexcom has addressed these reliability issues head-on by resolving supplier component problems and improving sensor performance metrics. The company’s recent presentations and data indicate that customer complaints have decreased, supporting the notion that the issues are being effectively managed. Jennings remains optimistic about Dexcom’s market position and the potential for stable share trends, reinforcing his Buy rating.
According to TipRanks, Jennings is a 3-star analyst with an average return of 0.9% and a 48.59% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic.